Axxora (UK) Limited 03033257 false 2023-08-01 2024-07-31 2024-07-31 The principal activity of the company is that of a holding company for Enzo Life Sciences (UK) Limited. Digita Accounts Production Advanced 6.30.9574.0 true true false false 03033257 2023-08-01 2024-07-31 03033257 2024-07-31 03033257 core:RetainedEarningsAccumulatedLosses 2024-07-31 03033257 core:ShareCapital 2024-07-31 03033257 core:SharePremium 2024-07-31 03033257 core:CurrentFinancialInstruments 2024-07-31 03033257 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 03033257 core:CostValuation 2024-07-31 03033257 bus:SmallEntities 2023-08-01 2024-07-31 03033257 bus:Audited 2023-08-01 2024-07-31 03033257 bus:FilletedAccounts 2023-08-01 2024-07-31 03033257 bus:SmallCompaniesRegimeForAccounts 2023-08-01 2024-07-31 03033257 bus:RegisteredOffice 2023-08-01 2024-07-31 03033257 bus:Director8 2023-08-01 2024-07-31 03033257 bus:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 03033257 1 2023-08-01 2024-07-31 03033257 countries:AllCountries 2023-08-01 2024-07-31 03033257 2022-08-01 2023-07-31 03033257 2023-07-31 03033257 core:RetainedEarningsAccumulatedLosses 2023-07-31 03033257 core:ShareCapital 2023-07-31 03033257 core:SharePremium 2023-07-31 03033257 core:CurrentFinancialInstruments 2023-07-31 03033257 core:CurrentFinancialInstruments core:WithinOneYear 2023-07-31 03033257 core:CostValuation 2023-07-31 iso4217:GBP xbrli:pure

Registration number: 03033257

Axxora (UK) Limited

Filleted Financial Statements

for the Year Ended 31 July 2024

 

Axxora (UK) Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 6

 

Axxora (UK) Limited

Company Information

Director

K A Cannon

Registered office

1 Colleton Crescent
Exeter
Devon
EX2 4DG

Auditors

Thompson Jenner LLP
Statutory Auditors
1 Colleton Crescent
Exeter
Devon
EX2 4DG

 

Axxora (UK) Limited

(Registration number: 03033257)
Balance Sheet as at 31 July 2024

Note

2024
£

2023
£

Fixed assets

 

Investments

6

2,303,201

2,303,201

Current assets

 

Debtors

7

57,547

57,381

Creditors: Amounts falling due within one year

8

(3,310,915)

(3,093,784)

Net current liabilities

 

(3,253,368)

(3,036,403)

Net liabilities

 

(950,167)

(733,202)

Capital and reserves

 

Called up share capital

100,000

100,000

Share premium reserve

564,157

564,157

Retained earnings

(1,614,324)

(1,397,359)

Shareholders' deficit

 

(950,167)

(733,202)

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 28 April 2025
 

.........................................
K A Cannon
Director

   
     
 

Axxora (UK) Limited

Notes to the Financial Statements for the Year Ended 31 July 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
1 Colleton Crescent
Exeter
Devon
EX2 4DG

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Group accounts not prepared

The company is part of a small group. The company has taken advantage of the exemption provided by Section 399 (2A) of the Companies Act 2006 and has not prepared group accounts.

Going concern

The company has made a loss during the year ended 31 July 2024 and has net current liabilities and net liabilities. The directors are confident that the company can trade profitably in the future.

The company has received confirmation of continued support from its parent company Enzo Life Sciences Overseas Holding Co. Inc.& the ultimate controlling party Enzo Bicochem Inc.

Audit report

The Independent Auditors' Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 28 April 2025 was Mr Jonathan Westley, who signed for and on behalf of Thompson Jenner LLP.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Axxora (UK) Limited

Notes to the Financial Statements for the Year Ended 31 July 2024

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

4

Interest payable and similar charges

Interest payables includes £216,960 (2023 - £176,155) payable on loans from group companies.

5

Loss before tax

Arrived at after charging/(crediting)

2024
£

2023
£

Foreign exchange gains/losses

5

(1,911)

 

Axxora (UK) Limited

Notes to the Financial Statements for the Year Ended 31 July 2024

6

Investments

2024
£

2023
£

Investments in subsidiaries

2,303,201

2,303,201

Subsidiaries

£

Cost or valuation

At 1 August 2023

2,303,201

At 31 July 2024

2,303,201

Carrying amount

At 31 July 2024

2,303,201

At 31 July 2023

2,303,201

7

Debtors

2024
£

2023
£

Amounts owed by group undertakings and undertakings in which the company has a participating interest

57,547

57,381

Total current trade and other debtors

57,547

57,381

8

Creditors

2024
£

2023
£

Due within one year

Amounts owed to group undertakings and undertakings in which the company has a participating interest

3,310,915

3,093,784

9

Contingent assets

The company has an unprovided deferred tax asset in respect of tax losses available to be set off against future taxable profits. This asset is valued at £289,386 (2023: £235,145) and is calculated using a tax rate of 25% (2023: 25%). Deferred tax balances are not discounted.

10

Related party transactions

The company has taken advantage of the exemptions in FRS 102 Section 1A "Related Party Disclosures" from disclosing transactions with other members of the group and key management personnel.

 

Axxora (UK) Limited

Notes to the Financial Statements for the Year Ended 31 July 2024

11

Parent and ultimate parent undertaking

The parent company is Enzo Life Sciences Overseas Holding Co, Inc. a company incorporated in the United States of America.

The company is ultimately controlled by Enzo Biochem Inc.,a company listed on the New York Stock Exchange.

Copies of the accounts are available on www.enzo.com, and also from:

Patricia Eckert
Chief Financial Officer
21 Executive Blvd, Farmingdale, NY 11735
New York